香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容所產生或因依賴 該等內容而引致的任何損失承擔任何責任。 Jiangsu Hengrui Pharmaceuticals Co., Ltd. 江蘇恒瑞醫藥股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：1276） 於本公告日期，董事會成員包括(i)執行董事孫飄揚先生、戴洪斌先生、馮佶女 士、張連山先生、江寧軍先生及孫杰平先生；(ii)非執行董事郭叢照女士；及(iii) 獨立非執行董事董家鴻先生、曾慶生先生、孫金雲先生及周紀恩先生。 证券代码：600276 证券简称：恒瑞医药 公告编号：临 2025-137 江苏恒瑞医药股份有限公司 关于回购公司 A 股股份的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 海外監管公告 本公告乃根據香港聯合交易所有限公司證券上市規則第13.10B條刊發。 根據中華人民共和國的有關法例規定，江蘇恒瑞醫藥 ...

Core Viewpoint - Heng Rui Medicine's subsidiary, Suzhou Shengdiya Biopharmaceutical Co., Ltd., has received approval from the National Medical Products Administration for the clinical trial of SHR-A2009, a novel antibody-drug conjugate targeting HER3 [1] Company Summary - SHR-A2009 is designed to specifically bind to HER3 on the surface of tumor cells, leading to internalization and subsequent release of cytotoxic agents within lysosomes to kill cancer cells [1] - This drug is notable as there are currently no similar drugs approved for market globally [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容所產生或因依賴 該等內容而引致的任何損失承擔任何責任。 Jiangsu Hengrui Pharmaceuticals Co., Ltd. 江蘇恒瑞醫藥股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：1276） 孫飄揚先生 中國上海 2025年9月2日 於本公告日期，董事會成員包括(i)執行董事孫飄揚先生、戴洪斌先生、馮佶女 士、張連山先生、江寧軍先生及孫杰平先生；(ii)非執行董事郭叢照女士；及(iii) 獨立非執行董事董家鴻先生、曾慶生先生、孫金雲先生及周紀恩先生。 证券代码：600276 证券简称：恒瑞医药 公告编号：临 2025-136 海外監管公告 本公告乃根據香港聯合交易所有限公司證券上市規則第13.10B條刊發。 根據中華人民共和國的有關法例規定，江蘇恒瑞醫藥股份有限公司（「本公司」）在 上海證券交易所網站( www.sse.com.cn )刊發了以下公告。茲載列如下，僅供參閱。 承董事會命 江蘇恒瑞醫藥股份有限公司 董事長 ...

9月2日，济南市召开"深入实施工业强市发展战略"主题系列新闻发布会——商河县专场。 据介绍，商河经济开发区强化项目招引，发展后劲持续增强。今年以来，已签约项目17个，其中过亿元 项目8个、过10亿元项目2个。 同时，商河经济开发区聚焦恒瑞医药（600276）、广日电梯等链主企业，产发健康医药产业谷、高端装 备制造产业园等"园中园"，以及未利用土地、闲置厂房等加大招引力度。截至目前，已累计策划项目41 个，新签约入驻"园中园"项目9个、利用厂房3.8万平方米；出让土地837.5亩。 商河经济开发区不断提升政务服务质效：围绕签约落地-开工建设-投产达效全周期，承接41项县级审批 权限，推动80%以上审批事项实现"园区事、园区办"，高频审批事项办理时限平均缩短1/3以上，促进企 业放心投资、安心发展；今年以来，为13个重点项目量身绘制"思维导图"，明确流程环节、时间节点与 责任人员，通过导图细化节点，提前介入关键环节，实时协调堵点问题，审勘同步、并联审批，推动项 目各环节衔接效率提升20%以上；今年以来，累计帮助30余家企业、项目解决融资需求4.7亿余元，帮 助34家企业解决用工需求820余人，助力16家企业深化供 ...

Macro Dynamics - The China-Shanghai Cooperation Organization Green Industry Cooperation Platform was officially launched in Tianjin, aiming to enhance dialogue, promote practical project cooperation, and strengthen green standards alignment among member countries [2] - The platform will focus on integrating green industry supply chains and facilitating the joint research and promotion of advanced green technologies [2] Software Industry - In the first seven months of 2025, China's software and information technology services industry reported a total profit of 108.9 billion yuan, reflecting a year-on-year growth of 12.4% [3] - Software business revenue reached 832.46 billion yuan, with a year-on-year increase of 12.3%, while software exports amounted to 33.98 billion USD, growing by 5.2% [3] Real Estate - Hunan Yueyang launched a housing subsidy program offering up to 200,000 yuan for home purchases in designated urban areas, effective from September 1 to November 15, 2025 [4][5] Financial Institutions - Xun Yugen has been appointed as the Chief Economist and Director of the Economic Research Institute at Guosen Securities, bringing 18 years of experience in securities research [7] - The Finance Minister of Pakistan, Aoran Zeb, visited the Industrial and Commercial Bank of China to discuss macroeconomic conditions and deepen economic and financial cooperation [8] - China Life Insurance's subsidiary has invested 1 billion yuan in a newly established venture capital fund focused on private equity investments [9] Market Data - The Shanghai Composite Index fell by 0.45%, with significant declines in the CPO concept and a strong performance in the banking sector [10] - The total margin financing balance across both exchanges increased by 35.396 billion yuan, reaching 2.273496 trillion yuan [11] Company Dynamics - Tianpu Co., Ltd. announced a potential suspension of trading due to significant stock price fluctuations, with an accumulated increase of 100% over eight consecutive trading days [14] - Western Gold reported normal production and operational conditions, despite a 20% increase in stock price over three days [15] - Hengrui Medicine received approval for clinical trials of two new drugs, HRS-7172 and SHR-A2009, which are innovative treatments for cancer [16]

Core Viewpoint - Shanghai Heng Rui Medicine Co., Ltd. has received acceptance for the clinical trial application of Leuprolide Acetate Microspheres, a Class 3 chemical drug, which has already surpassed annual sales of 5 billion yuan in the domestic market [1][4]. Group 1: Market Overview - Leuprolide Acetate is a synthetic peptide analog of gonadotropin-releasing hormone (GnRH), primarily used for treating diseases related to elevated sex hormone levels, such as endometriosis, uterine fibroids, precocious puberty, prostate cancer, and breast cancer [3]. - The domestic market for Leuprolide Acetate has shown stable sales exceeding 5 billion yuan over the past three years, with sales figures of 5.206 billion yuan in 2022, 5.391 billion yuan in 2023, and projected 5.623 billion yuan in 2024, indicating a steady growth trend [4][6]. Group 2: Competitive Landscape - The original manufacturer, Takeda, and AbbVie developed the injectable Leuprolide Acetate microspheres, which were approved by the FDA in 1989 and have achieved significant success. In China, it was approved in 2000 and is included in the national medical insurance category B [6]. - Currently, there are two domestic companies, Lijun Group and Beijing Bont Pharmaceutical, that hold production licenses for Leuprolide Acetate long-acting microspheres, with Lijun Group being the first to obtain approval for the generic version [8][10]. - The sales share of Lijun Pharmaceutical's Leuprolide Acetate microspheres is the highest at 39.85%, followed by the original manufacturer Takeda [10]. Group 3: Future Market Potential - The market for injectable Leuprolide Acetate microspheres is expected to reach 6.8 billion yuan by 2025 and exceed 8.7 billion yuan by 2030, indicating a promising outlook for the product [6]. - The domestic market for microsphere formulations has grown significantly, with sales increasing from 2.5 billion yuan in 2015 to 7.9 billion yuan in 2023, and the market share rising from 34.6% to 49.7% [13][15]. - As the technology for microsphere formulations matures and pharmaceutical companies continue to innovate, Leuprolide Acetate microspheres are expected to play a crucial role in building competitive advantages and capturing market share [17].

Core Insights - The competitiveness of the biopharmaceutical industry ultimately reflects the cluster effect [1][11] - The biopharmaceutical industry is a core track of global technological revolution and industrial transformation, serving as a key indicator of regional economic high-quality development [2] Industry Development - The Yangtze River Delta region, centered around Shanghai Zhangjiang and Suzhou BioBAY, has established a first-mover advantage in the biopharmaceutical field due to early policy layouts, dense research resources, and a complete industrial chain [2] - Guangzhou Huangpu District has not lagged despite being a latecomer; it has optimized its policy system, built talent aggregation platforms, and focused on breakthroughs in niche markets, gradually compensating for industrial chain shortcomings [2][12] Key Companies and Innovations - Yunzhou Biotech, founded by Dr. Lan Tian in Huangpu District in 2014, focuses on gene delivery, a critical link between basic research and clinical application [3] - The company developed the world's first intelligent design and ordering platform for gene carriers, integrating over 120 carrier systems and more than 2 million carrier components, significantly lowering the barriers for researchers [4][5] - Yunzhou Biotech has become the world's largest custom gene carrier supplier, serving over 7,000 institutions in more than 130 countries, with a cumulative delivery of over 1 million carriers by September 2024 [5][6] Market Position and Achievements - In 2023, Yunzhou Biotech achieved a valuation of 7 billion, becoming a unicorn and the first biopharmaceutical company in Guangzhou to reach this status [6] - The company has established a full-service capability in the gene drug development chain, including CRO and CDMO services, with its products approved for clinical trials in the U.S. [6][7] Competitive Landscape - Innovation in drug development is a core competitive advantage in the biopharmaceutical industry, with companies like Kangfang Biopharma emerging as leaders in the field [8] - Kangfang Biopharma has developed over 50 innovative drug candidates, with 24 products undergoing clinical trials, and has successfully commercialized 7 first-class new drugs [10] Ecosystem and Collaboration - Huangpu District's "bending overtaking" is not merely the success of a single enterprise but a result of creating a quality industrial ecosystem that fosters collaboration between leading external companies and local enterprises [12] - The presence of major companies like Hengrui Medicine and Nuocheng Jianhua in Huangpu has attracted a network of supporting enterprises, enhancing the regional industrial chain [13][14]

Investment Rating - The report maintains a strong buy rating for the pharmaceutical sector, indicating a bullish outlook for the industry [3]. Core Insights - The pharmaceutical sector is expected to experience a broad rally, driven by innovative drugs leading the charge. The sector index showed a notable upward trend in the first half of 2025, particularly in April, with a valuation premium of 275.19%, significantly above historical averages [4][18]. - Public funds are increasingly favoring pharmaceutical stocks, particularly in innovative drugs and medical devices, supported by stable growth in basic medical insurance funds [4][22]. Section Summaries 1. Market Performance - The pharmaceutical sector has shown a strong upward trend since Q3 2024, outperforming the broader market indices. The sector index rose by 24.51% from the beginning of 2025 to August 29, 2025, surpassing the Shanghai and Shenzhen 300 index by 11.07 percentage points [11][12]. - Medical services and chemical raw materials have performed particularly well, with medical services up by 80.24% and chemical raw materials up by 53.67% as of August 28, 2025 [17]. 2. Industry Overview - The pharmaceutical manufacturing industry has shown resilience, with stable revenue growth and a healthy operating environment for basic medical insurance funds. The overall revenue of the pharmaceutical manufacturing industry has experienced fluctuations but is on a recovery path [31][35]. - The innovative drug business development (BD) has seen explosive growth, with China becoming a hotspot for multinational corporations (MNCs) seeking partnerships. The total transaction amount for BD in 2024 reached a record high of $640.8 billion, with significant contributions from overseas transactions [36][38]. 3. Subsector Analysis - Innovative drugs are leading the growth, with 21 A-share innovative drug companies reporting a revenue of 28.69 billion yuan in the first half of 2025, a year-on-year increase of 42%. The net profit loss has narrowed significantly, indicating a positive trend in profitability [56]. - The medical device sector is also expected to see a turning point in the second half of 2025, with a 62.75% year-on-year growth in the overall bidding market for medical devices in the first half of 2025, exceeding 80 billion yuan [52].

北京商报讯（记者 王寅浩 实习记者 宋雨盈）9月2日，恒瑞医药发布公告称，公司近日收到国家药品监 督管理局核准签发关于HRS—7172片的《药物临床试验批准通知书》，同意该品单药在携带RAS突变或 扩增的晚期实体瘤患者中开展临床试验。 ...

Core Viewpoint - Heng Rui Medicine announced that its subsidiary, Suzhou Shengdiya Biopharmaceutical Co., Ltd., received approval from the National Medical Products Administration for the clinical trial of SHR-A2009, an antibody-drug conjugate targeting HER3, aimed at treating advanced solid tumors [1] Group 1 - The clinical trial will focus on the safety, tolerability, and efficacy of SHR-A2009 in combination with anti-tumor therapy in patients with advanced solid tumors [1] - SHR-A2009 specifically binds to HER3 on the surface of tumor cells, leading to internalization and subsequent release of cytotoxic agents within lysosomes to kill cancer cells [1]